scispace - formally typeset
I

Ian O. Ellis

Researcher at University of Nottingham

Publications -  1071
Citations -  84964

Ian O. Ellis is an academic researcher from University of Nottingham. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 126, co-authored 1051 publications receiving 75435 citations. Previous affiliations of Ian O. Ellis include Mansoura University & Curie Institute.

Papers
More filters
Journal ArticleDOI

Breast carcinoma with basal phenotype: mammographic findings.

TL;DR: Screening-detected breast tumors with a basal phenotype have a mammographic appearance different from that of nonbasal tumors, which may explain the good prognostic value of mammographic spiculation reported in previous studies.
Journal ArticleDOI

Histological grading of breast cancer on needle core biopsy: the role of immunohistochemical assessment of proliferation.

TL;DR: Kwok T C, Rakha E A, Lee A H S, Grainge M, Green A R, Ellis I O & Powe D G (2010) Histopathology57, 212–219.
Journal ArticleDOI

When have mammographic calcifications been adequately sampled at needle core biopsy

TL;DR: To ensure adequate sampling of calcification at core biopsy, an optimum of either three or more cores containing calcium or five or more flecks of calcium in total is required, which ensures a high pre-operative diagnosis rate for malignant microcalcifications.
Journal ArticleDOI

Microdochectomy for single‐duct discharge from the nipple

TL;DR: Review of 97 consecutive patients undergoing microdochectomy between 1980 and 1987 revealed a total of eight patients with ductal carcinoma in situ, and it is suggested an expectant policy in cases where the mammogram is normal, omitting routine microdocHEctomy.
Journal ArticleDOI

External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme

TL;DR: Data from a significant proportion of participating laboratories show that further steps are required, including those taken via review of performance under schemes such as NEQAS, to improve quality of HER2 testing by FISH in the “real world”.